Dashboard
Manage Tickers

NOVNOV Inc.

NYSE nov.com


$ 18.84 $ -0.29 (-1.52 %)    

Friday, 10-May-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 18.84
$ 19.16
$ 0.00 x 0
$ 0.00 x 0
$ 18.84 - $ 19.20
$ 13.89 - $ 21.73
2,548,421
na
7.48B
$ 1.10
$ 7.59
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-26-2024 03-31-2024 10-Q
2 02-14-2024 12-31-2023 10-K
3 10-27-2023 09-30-2023 10-Q
4 07-27-2023 06-30-2023 10-Q
5 04-27-2023 03-31-2023 10-Q
6 02-14-2023 12-31-2022 10-K
7 10-28-2022 09-30-2022 10-Q
8 07-28-2022 06-30-2022 10-Q
9 04-29-2022 03-31-2022 10-Q
10 02-11-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 07-28-2021 06-30-2021 10-Q
13 04-28-2021 03-31-2021 10-Q
14 02-12-2021 12-31-2020 10-K
15 10-27-2020 09-30-2020 10-Q
16 07-28-2020 06-30-2020 10-Q
17 04-28-2020 03-31-2020 10-Q
18 02-13-2020 12-31-2019 10-K
19 10-30-2019 09-30-2019 10-Q
20 07-31-2019 06-30-2019 10-Q
21 04-26-2019 03-31-2019 10-Q
22 02-14-2019 12-31-2018 10-K
23 10-26-2018 09-30-2018 10-Q
24 07-27-2018 06-30-2018 10-Q
25 04-27-2018 03-31-2018 10-Q
26 02-16-2018 12-31-2017 10-K
27 10-27-2017 09-30-2017 10-Q
28 07-28-2017 06-30-2017 10-Q
29 04-28-2017 03-31-2017 10-Q
30 02-17-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 08-03-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 08-05-2015 06-30-2015 10-Q
37 05-05-2015 03-31-2015 10-Q
38 02-17-2015 12-31-2014 10-K
39 11-03-2014 09-30-2014 10-Q
40 08-04-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

breaking-down-nov-6-analysts-share-their-views
Breaking Down NOV: 6 Analysts Share Their ...
04/29/2024 17:01:27

td-cowen-maintains-buy-on-nov-lowers-price-target-to-26
TD Cowen Maintains Buy on NOV, Lowers Pric...
04/29/2024 17:00:21

TD Cowen analyst Marc Bianchi maintains NOV (NYSE:NOV) with a Buy and lowers the price target from $27 to $26.

nov-q1-eps-030-beats-027-estimate-sales-215b-beat-211b-estimate
NOV Q1 EPS $0.30 Beats $0.27 Estimate, Sal...
04/25/2024 22:10:56

NOV (NYSE:NOV) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.27 by 11.11 perce...

expert-ratings-for-nov
Expert Ratings For NOV
04/08/2024 16:00:26

susquehanna-maintains-positive-on-nov-maintains-26-price-target
Susquehanna Maintains Positive on NOV, Mai...
04/08/2024 15:27:26

Susquehanna analyst Charles Minervino maintains NOV (NYSE:NOV) with a Positive and maintains $26 price target.

arcosa-illuminates-its-portfolio-with-180m-ameron-pole-products-acquisition
Arcosa Illuminates Its Portfolio with $180...
03/11/2024 14:48:14

Arcosa Inc seals $180 million deal to acquire Ameron Pole Products from NOV Inc. Ameron, founded in 1970, specializes in premiu...

Core News & Articles
Arcosa Announces Agreement To Acquire Amer...
03/11/2024 12:09:19

Acquisition Provides Additional Scale to Engineered Structures in Attractive Infrastructure Markets and is Accretive to Overall...

piper-sandler-maintains-neutral-rating-for-nov-heres-what-you-need-to-know
Piper Sandler Maintains Neutral Rating for...
02/20/2024 17:00:18

in-depth-examination-of-5-analyst-recommendations-for-nov
In-Depth Examination Of 5 Analyst Recommen...
02/06/2024 16:00:25

rbc-capital-reiterates-sector-perform-on-nov-maintains-24-price-target
RBC Capital Reiterates Sector Perform on N...
02/06/2024 15:58:59

RBC Capital analyst Keith Mackey reiterates NOV (NYSE:NOV) with a Sector Perform and maintains $24 price target.

stifel-maintains-buy-on-nov-lowers-price-target-to-26-report-released-on--4-february-2024
Stifel Maintains Buy on NOV, Lowers Price ...
02/05/2024 21:13:45

Stifel analyst Stephen Gengaro maintains NOV (NYSE:NOV) with a Buy and lowers the price target from $28 to $26.

raymond-james-maintains-outperform-on-nov-lowers-price-target-to-25
Raymond James Maintains Outperform on NOV,...
02/05/2024 12:34:50

Raymond James analyst James Rollyson maintains NOV (NYSE:NOV) with a Outperform and lowers the price target from $28 to $25.

nov-q4-eps-151-beats-041-estimate-sales-234b-beat-226b-estimate
NOV Q4 EPS $1.51 Beats $0.41 Estimate, Sal...
02/01/2024 22:38:44

NOV (NYSE:NOV) reported quarterly earnings of $1.51 per share which beat the analyst consensus estimate of $0.41 by 268.29 perc...

earnings-scheduled-for-february-1-2024
Earnings Scheduled For February 1, 2024
02/01/2024 10:03:12

Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NY...

earnings-outlook-for-nov
Earnings Outlook For NOV
01/31/2024 15:01:19

why-ups-shares-are-trading-lower-by-8-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why UPS Shares Are Trading Lower By 8%? He...
01/30/2024 18:18:27

Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-e...

benchmark-downgrades-nov-to-hold
Benchmark Downgrades NOV to Hold
01/16/2024 20:07:18

Benchmark analyst Kurt Hallead downgrades NOV (NYSE:NOV) from Buy to Hold.

td-cowen-maintains-outperform-on-nov-raises-price-target-to-29
TD Cowen Maintains Outperform on NOV, Rais...
12/12/2023 12:55:01

TD Cowen analyst Marc Bianchi maintains NOV (NYSE:NOV) with a Outperform and raises the price target from $28 to $29.

the-latest-analyst-ratings-for-nov
The Latest Analyst Ratings for NOV
12/08/2023 12:00:18

jp-morgan-upgrades-nov-to-overweight-announces-25-price-target
JP Morgan Upgrades NOV to Overweight, Anno...
12/08/2023 11:40:54

JP Morgan analyst Arun Jayaram upgrades NOV (NYSE:NOV) from Neutral to Overweight and announces $25 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION